SCHEMBL84333

SCHEMBL84333

C1CN2CCC1C2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6208613 0.96
Bromide SCHEMBL4969616 0.96
Iodide SCHEMBL4968720 0.96
Ammonia Solution, Strong SCHEMBL2942851 0.96
SCHEMBL2124820 0.90 CHRNA7 (0.38)
SCHEMBL24409361 0.87
SCHEMBL28564 0.87
Hydrochloric Acid SCHEMBL2706385 0.85
SCHEMBL2148332 0.85
SCHEMBL3399160 0.85

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2704 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122070278-A Bifunctional protein degradation agent containing aryl substituted heteroaryl and application thereof 标新生物医药科技(上海)有限公司 2026-05-19 CN claimed
US-20250171420-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME MONTE ROSA THERAPEUTICS AG (CH) 2025-05-29 US claimed
US-20250154109-A1 SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE LATIGO BIOTHERAPEUTICS, INC 2025-05-15 US claimed
EP-4547666-A1 METHODS FOR TREATMENT OF CANCER Frontier Medicines Corporation (US) 2025-05-07 EP claimed
EP-4540240-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME Monte Rosa Therapeutics AG (CH) 2025-04-23 EP claimed
WO-2025029890-A1 SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE LATIGO BIOTHERAPEUTICS, INC. (US) 2025-02-06 WO claimed
US-12195445-B2 2-amino-N-heteroaryl-nicotinamides as Nav1.8 inhibitors MERCK SHARP & DOHME LLC (US) 2025-01-14 US claimed
CN-119233970-A Nitrogen-containing heterocyclic compound, and preparation method and application thereof 纽欧申医药(上海)有限公司 2024-12-31 CN claimed
EP-4472966-A2 SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE Latigo Biotherapeutics, Inc. (US) 2024-12-11 EP claimed
WO-2024217539-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF 纽欧申医药(上海)有限公司 2024-10-24 WO claimed
US-5185320-A Antibiotics GRUPPO LEPETIT S.P.A. (IT) 1993-02-09 US claimed
EP-0307141-B1 OXAZOLES AND THIAZOLES FOR THE TREATMENT OF SENILE DEMENTIA MERCK SHARP &amp; DOHME LTD. (GB) 1993-01-13 EP claimed
EP-0492902-A1 Substituted pyridine derivatives for use in the treatment of glaucoma MERCK SHARP &amp; DOHME LTD. (GB) 1992-07-01 EP claimed
WO-1992001690-A1 NOVEL SPIRO-ISOXAZOLIDINE DERIVATIVES AS CHOLINERGIC AGENTS FISONS CORPORATION (US) 1992-02-06 WO claimed
EP-0398617-A2 Process for resolving 1-azabicyclo [2.2.1]heptane-3-carboxylates MERCK SHARP & DOHME LTD. (GB) 1990-11-22 EP claimed
EP-0350118-A2 Spiro-azabicyclic muscarinic agonists MERCK SHARP & DOHME LTD. (GB) 1990-01-10 EP claimed
EP-0307141-A2 Oxazoles and thiazoles for the treatment of senile dementia MERCK SHARP &amp; DOHME LTD. (GB) 1989-03-15 EP claimed
EP-0307140-A1 Oxadiazolyl-azabicycloheptanes for the treatment of senile dementia MERCK SHARP & DOHME LTD. (GB) 1989-03-15 EP claimed
EP-0301729-A1 Pro-drugs for oxadiazole muscarinic agonists MERCK SHARP & DOHME LTD. (GB) 1989-02-01 EP claimed
EP-0239309-A2 Oxadiazoles useful in the treatment of senile dementia MERCK SHARP & DOHME LTD. (GB) 1987-09-30 EP claimed